Bar Admissions

• New York
• Delaware

Court Admissions

• US District Court, Districts of Delaware and Colorado
• US Court of Appeals, Federal and Second Circuits
• US Supreme Court

• Georgetown University, J.D., 1991: magna cum laude, Order of the Coif
• Pennsylvania State University, B.S., Biology, 1986

• Recognized by Chambers USA for Intellectual Property: Patent (2023-2026)
• Recognized by Best Lawyers in America for Biotechnology and Life Sciences Practice, Litigation - Intellectual Property, and Corporate Governance Law in New York, NY (2024-2025)
• Named a “National Practice Area Star” and “Litigation Star” in Intellectual Property by Benchmark Litigation (2021-2025)
• Consecutively recommended by The Legal 500 US for Patents: Litigation (Full Coverage) (2016-2024) and Healthcare: Life Sciences (2016-2026)
• Named Hatch-Waxman Litigator of the Year - Branded by LMG Life Sciences (2020), and repeatedly shortlisted for the award (2015-2019, 2022-2024)
• Named a “Life Science Star” for Hatch-Waxman Patent Litigation, Patent Strategy & Management, General Patent Litigation by LMG Life Sciences (2015-2025)
• Listed among “The World’s Leading Patent Litigators,” IAM 250
• Repeatedly recognized as a leading attorney in IAM Patent 1000
• Included in the 2023 edition of the IAM Global Leaders Guide
• Recognized by Managing Intellectual Property’s “Top 250 Women in IP” global list (2018-2025)
• Named a “National Patent Star” by Managing Intellectual Property (2023)
• Named to Managing Intellectual Property’s “IP Stars” list (2018-2025)
• Named a “National Top 30 Life Sciences Practitioner in the US” in Euromoney’s “Best of the Best USA Expert Guide” (2021)
• Recognized in Euromoney’s “Best of the Best USA Expert Guide” (multiple years)
• Shortlisted, Best Woman in Patent Law, Euromoney (2014)
• Recognized in Euromoney’s “Women in Business Law Expert Guides” (2013)
• Named a “Client Service All-Star” by The BTI Consulting Group (2021, 2022)
• Selected to “Super Lawyers” list for Intellectual Property Litigation in New York (multiple years)

Co-Founder

• WIN: Women in Intellectual Property Network

Member

• American Bar Association
• New York State Bar Association
• Delaware Bar Association
• New York Intellectual Property Law Association
• Delaware Intellectual Property Law Association
• National Association of Women Lawyers (NAWL)
• ChIPs

Author

• “AI and Life Sciences Patents: Separating Myth From Reality,” New York Law Journal (March 2020)
• “Potential Crisis in Patent Law? Patent Eligibility of Medical Advances,” Legal Media Group's Expert Guides (August 2016)
• “Solving the mystery of the patent dance,” Life Sciences Intellectual Property Review (May 2016)
• Contributing Editor, The Sedona Conference Commentary on Patent Litigation Best Practices: “Use of Experts, Daubert, and Motions in Limine” Chapter (December 2015)
• “Supreme Court to Decide Legality of Reverse-Payment Settlements in Paragraph IV Disputes,” Financier Worldwide Magazine (March 2013)
• “Hatch-Waxman Act: Overview,” Practical Law Company (March 2013)
• “Proving Obviousness? Understanding the Implications of In re Cyclobenzaprine,” China Intellectual Property Magazine (December 2012)
• “New Uncertainty In Subject Matter Eligibility For Biopharma Products,” Financier Worldwide Magazine (July 2012)
• “The Legality of Reverse Payment Settlements in Paragraph IV Disputes,” IAM Magazine (July/August 2012)
• “Pay-for-delay – Payment Settlements in Paragraph IV Hatch-Waxman Disputes,” Financier Worldwide Magazine (April 2012)
• “Patent Pitfalls and Opportunities for Foreign Companies Operating in the US,” China Legal Review (September 2010)
• “Significance of Takeda v. Mylan,” IP LAW 360 (March 6, 2009)
• “A sea change in wilful infringement,” Intellectual Asset Management (October/November 2007)
• “Amending of § 337 to Obtain Gatt Consistency and Retain Border Protection,” Law and Policy in International Business, Vol. 22 (1991).

Featured

• Leading by Example: Elevating Women through Intentionality, ABA Landslide (December 2019)
• “Be All In: A Conversation with Lisa Pensabene,” Ms. JD (February 2015)

Speaker

• Panelist, "General Counsel Roundtable," Pro Bono Institute (October 26, 2021)
• Panelist, “World Recognition of Distinguished General Counsel: Honoring Jonathan Graham & The Law Department of Amgen,” Director’s Roundtable (April 20, 2021)
• Panelist, 2021 Sedona Conference on Remote Case management (June 10, 2021)
• Preconference Seminar on Careers in IP Law, ACI Women Leaders in IP Law (March 9, 2021)
• "The Present State of Paragraph IV Litigation and Its Impact on the Pharmaceutical Industry: Legal Analyses and Business Prognoses" ACI's 13th Annual Paragraph IV Disputes Conference (April 29, 2019)
• “What Can Medical Biotechnology Learn from Patent Litigation in Industrial and Agricultural Biotech?” Bio IP Counsels Committee Conference (November 14-16, 2018)
• “The Federal Judges Speak on Paragraph IV Litigation,” ACI’s 12th Annual Paragraph IV Disputes Conference (April 23, 2018)
• “Obviousness Update for PIV Litigation: Latest Developments in the Federal Courts and PTAB,” ACI’s 11th Annual Paragraph IV Disputes Conference (April 24, 2017)
• “Goliath vs. Goliath Patent Wars,” BIO IP Counsels Committee Conference (November 14, 2016)
• “On Sale Bar in a Hatch-Waxman Setting,” ACI’s 10th Annual Paragraph IV Disputes Conference (April 25-27, 2016)
• “The Evolving Landscape of Biosimilars Litigation in the United States,” BIO IP Counsels Committee Conference (November 16, 2015)
• “Understanding Biosimilars Law to Be Slow, Gradual Process,” Patent, Trademark & Copyright Journal, Bloomberg BNA (November 16, 2015)
• “Biotech and Diagnostic Patents Risks: What You Need to Know,” The Knowledge Group (June 21, 2015)
• “Biosimilars Litigation: What’s Happening on the Dance Floor?,” NJIPLA Patent Litigation Seminar (March 18, 2015)
• “Biosimilars Strategy Update,” BIO IP Counsels Committee Conference (November 10, 2014)
• “Strategies for Hatch-Waxman Trials,” ACI Hatch-Waxman Master Class Conference (October 1, 2014)
• “Supreme Court Developments,” Organization for International Investment meeting of General Counsel (September 19, 2014)
• “Paragraph IV Disputes,” American Conference Institute (April 2014)
• “Bio War Games,” Bio IP Counsels Committee Conference, Biotechnology Industry Organization (November 6-8, 2013)
• “Maximizing Pharmaceutical Patent Lifecycles,” American Conference Institute (October 10, 2012)
• “Through the Eyes of One of Ordinary Skill in the Art,” 27th Annual Joint Patent Practice Seminar, Daiichi Sankyo Co. v. Matrix Laboratories Ltd. (Fed. Cir. 2010) (April 2011)
• “27th Annual Joint Patent Practice Seminar,” New York Intellectual Property Law Association (April 2011)
• “Managing the Risks Associated with Injunctions and At-Risk Launches During Litigation and Appeal,” American Conference Institute’s 2nd Annual Paragraph IV Disputes: Expert Insights on Hatch-Waxman Litigation Strategies for Brand Names and Generics (May 1, 2008)
• “Best Practices in Pharmaceutical Patent Litigation,” Polymorphism & Crystallization Forum 2004: Science, Technology & Intellectual Property (April 26, 2004)
• “Mentoring Programs - There is One That Will Work For You!” The 2004 Women’s Leadership Conference (March 18, 2004)
• “Walking the Tightrope: Work/Life Balance in the Profession,” Minority Corporate Counsel Association’s 4th Annual Creating Pathways to Diversity Conference (October 30, 2003)